Tempus wins FDA approval for tumor-only label on xT CDx genomic profiling test

Tempus Al

Tempus Al

TEM

0.00
  • FDA granted a tumor-only indication for Tempus xT CDx, expanding its companion diagnostic label to cover tumor-only genomic profiling.
  • Decision enables migration of its DNA solid tumor testing portfolio to FDA-cleared assays under unified ADLT pricing.
  • Tempus expects an estimated $200 average selling price uplift starting in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605290815BIZWIRE_USPR_____20260529_BW144345) on May 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.